Clinical pharmacokinetics of melatonin: a systematic review - PubMed (original) (raw)

Review

Clinical pharmacokinetics of melatonin: a systematic review

Nathja Groth Harpsøe et al. Eur J Clin Pharmacol. 2015 Aug.

Abstract

Purpose: The aim of the review was to provide an overview of studies investigating the pharmacokinetics of exogenous melatonin in humans and if possible, to provide recommendations for clinical use.

Methods: The review was conducted in accordance to PRISMA guidelines. A systematic literature search was performed in PubMed and Embase databases. The pharmacokinetic variables included maximal plasma/serum concentration (Cmax), time to maximal plasma/serum concentration (Tmax), elimination half-life (T1/2), area-under-the-curve plasma/serum concentrations (AUC), clearance (Cl), volume of distribution (VD), and bioavailability.

Results: The literature search identified 392 records. Twenty-two studies were included in the review. Melatonin dosages varied between 0.3 and 100 mg and were administered either orally or intravenously. Cmax ranged from 72.1 (10 ml/h; 0.02 mg, IV) to 101,163 pg/ml (100 mg, oral). Tmax ranged between 15 (2 mg) and 210 min (10 mg). T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral). Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral). Bioavailability of oral melatonin ranged from 9 to 33%. Pharmacokinetics was affected by age, caffeine, smoking, oral contraceptives, feeding status, and fluvoxamine. Critically ill patients displayed accelerated absorption and compromised elimination.

Conclusions: Despite methodological differences between the included studies, Tmax was approximately 50 min following oral immediate-release formulations of melatonin. T1/2 was 45 min in both administration routes. Cmax, AUC, Cl, and VD varied extensively between studies. Bioavailability of oral melatonin was approximately 15%.

PubMed Disclaimer

Similar articles

• Pharmacokinetics of oral and intravenous melatonin in healthy volunteers.
  Andersen LP, Werner MU, Rosenkilde MM, Harpsøe NG, Fuglsang H, Rosenberg J, Gögenur I. Andersen LP, et al. BMC Pharmacol Toxicol. 2016 Feb 19;17:8. doi: 10.1186/s40360-016-0052-2. BMC Pharmacol Toxicol. 2016. PMID: 26893170 Free PMC article. Clinical Trial.
• Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery.
  Harpsøe NG, Andersen LP, Mielke LV, Jønsson B, Jenstrup MT, Gögenur I, Rosenberg J. Harpsøe NG, et al. Clin Drug Investig. 2016 Dec;36(12):1045-1050. doi: 10.1007/s40261-016-0452-5. Clin Drug Investig. 2016. PMID: 27566320
• Clinical Pharmacokinetics of Metoprolol: A Systematic Review.
  Zamir A, Hussain I, Ur Rehman A, Ashraf W, Imran I, Saeed H, Majeed A, Alqahtani F, Rasool MF. Zamir A, et al. Clin Pharmacokinet. 2022 Aug;61(8):1095-1114. doi: 10.1007/s40262-022-01145-y. Epub 2022 Jun 28. Clin Pharmacokinet. 2022. PMID: 35764772
• Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems.
  Priano L, Esposti D, Esposti R, Castagna G, De Medici C, Fraschini F, Gasco MR, Mauro A. Priano L, et al. J Nanosci Nanotechnol. 2007 Oct;7(10):3596-601. doi: 10.1166/jnn.2007.809. J Nanosci Nanotechnol. 2007. PMID: 18330178
• Clinical pharmacokinetics of mizolastine.
  Lebrun-Vignes B, Diquet B, Chosidow O. Lebrun-Vignes B, et al. Clin Pharmacokinet. 2001;40(7):501-7. doi: 10.2165/00003088-200140070-00002. Clin Pharmacokinet. 2001. PMID: 11510627 Review.

Cited by

• Melatonin to Rescue the Aged Heart: Antiarrhythmic and Antioxidant Benefits.
  Segovia-Roldan M, Diez ER, Pueyo E. Segovia-Roldan M, et al. Oxid Med Cell Longev. 2021 Mar 13;2021:8876792. doi: 10.1155/2021/8876792. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 33791076 Free PMC article. Review.
• Is Melatonin the "Next Vitamin D"?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements.
  Minich DM, Henning M, Darley C, Fahoum M, Schuler CB, Frame J. Minich DM, et al. Nutrients. 2022 Sep 22;14(19):3934. doi: 10.3390/nu14193934. Nutrients. 2022. PMID: 36235587 Free PMC article. Review.
• The Role of Melatonin in Palliative Care #306.
  Waldman G, Pruskowski J, Arnold R. Waldman G, et al. J Palliat Med. 2016 May;19(5):568-9. doi: 10.1089/jpm.2016.0023. Epub 2016 Apr 20. J Palliat Med. 2016. PMID: 27096287 Free PMC article. No abstract available.
• Melatonin as a Therapy for Preterm Brain Injury: What Is the Evidence?
  Häusler S, Robertson NJ, Golhen K, van den Anker J, Tucker K, Felder TK. Häusler S, et al. Antioxidants (Basel). 2023 Aug 17;12(8):1630. doi: 10.3390/antiox12081630. Antioxidants (Basel). 2023. PMID: 37627625 Free PMC article. Review.
• Resting and Recharging: A Narrative Review of Strategies to Improve Sleep During Residency Training.
  Redinger J, Kabil E, Forkin KT, Kleiman AM, Dunn LK. Redinger J, et al. J Grad Med Educ. 2022 Aug;14(4):420-430. doi: 10.4300/JGME-D-21-01035.1. J Grad Med Educ. 2022. PMID: 35991104 Free PMC article. Review.

References

1. 1. J Gerontol A Biol Sci Med Sci. 1998 Jul;53(4):B293-8 - PubMed
2. 1. J Clin Pharmacol. 2008 Feb;48(2):240-5 - PubMed
3. 1. Br J Clin Pharmacol. 1985 Apr;19(4):517-21 - PubMed
4. 1. Int J Surg. 2010;8(5):336-41 - PubMed
5. 1. N Engl J Med. 1997 Apr 3;336(14):1028-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database